<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525133</url>
  </required_header>
  <id_info>
    <org_study_id>INN-CB-016</org_study_id>
    <nct_id>NCT02525133</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty</brief_title>
  <acronym>MATRIX-2</acronym>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the XaraColl® Bupivacaine Implant (300 mg Bupivacaine Hydrochloride) After Open Laparotomy Hernioplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innocoll</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innocoll</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled&#xD;
      efficacy and safety study of postoperative pain in adults who are scheduled for unilateral&#xD;
      inguinal hernioplasty via open laparotomy (tension-free technique).&#xD;
&#xD;
      Patients will assess their postoperative pain intensity (PI) using an 11-point numerical&#xD;
      rating scale (NRS) from 0 hour through 72 hours postoperatively.&#xD;
&#xD;
      The expected maximum study duration for each patient will be up to 60 days, including a&#xD;
      maximum 30-day screening period, the day of surgery and implantation, and a 30-day post&#xD;
      implantation period including treatment and follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled&#xD;
      study in adults who are scheduled for unilateral inguinal hernioplasty via open laparotomy&#xD;
      (tension-free technique). Patients will receive either 3 XaraColl Bupivacaine Implants each&#xD;
      containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose; or 3&#xD;
      placebo-sponges.&#xD;
&#xD;
      Three test article sponges will be implanted according to the patient's blinded treatment&#xD;
      assignment. Following surgery, patients will be transferred to a postanesthesia care unit&#xD;
      (PACU) and/or other postoperative recovery area for observation where they may receive&#xD;
      parenteral morphine as needed (rescue medication for breakthrough pain) and on request for&#xD;
      pain control. Once patients can tolerate oral medication, they will commence a standardized&#xD;
      oral analgesic regimen with additional PRN medication to manage breakthrough pain only when&#xD;
      it occurs.&#xD;
&#xD;
      Patients will assess their postoperative pain intensity (PI) using an 11-point numerical&#xD;
      rating scale (NRS) from 0 hour through 72 hours postoperatively.&#xD;
&#xD;
      Patients will be observed postoperatively for a minimum of 3 hours and may be discharged at&#xD;
      any time following completion of their 3-hour vital sign and PI assessments. Patients will be&#xD;
      contacted at approximately 6, 24 and 48 hours after implantation to ensure protocol&#xD;
      compliance and to perform safety assessments (including AEs and concomitant medications). At&#xD;
      72 hours, patients will return to the clinic to perform their final PI assessment, complete a&#xD;
      categorical assessment of their overall pain control, and for follow-up safety assessments.&#xD;
      They will also be asked to record the incidence of any ongoing or subsequent AEs (and any&#xD;
      associated treatment) through Day 7. Additional follow-up assessments for safety will be&#xD;
      performed at postoperative Day 7 (telephone call) and Days 15 and 30 (clinic visits).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 5, 2015</start_date>
  <completion_date type="Actual">April 22, 2016</completion_date>
  <primary_completion_date type="Actual">April 22, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SPI24</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>The primary efficacy variable (time-weighted sum of pain intensity from Time 0 through 24 hours [SPI24]) was compared once at a 2-sided 0.05 level. Therefore, no multiplicity adjustment was necessary for the primary efficacy analysis. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot;. Minimum value would be &quot;0&quot; and Maximum value would be 240. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI24 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TOpA24</measure>
    <time_frame>Time 0 through 24 hours</time_frame>
    <description>Total use of opioid analgesia (TOpA) from Time 0 through 24 hours (TOpA24) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had to use within a 24-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TOpA48</measure>
    <time_frame>Time 0 through 48 hours</time_frame>
    <description>Total use of opioid analgesia (TOpA) from Time 0 through 48 hours (TOpA48) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 48-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TOpA72</measure>
    <time_frame>Time 0 through 72 hours</time_frame>
    <description>Total use of opioid analgesia (TOpA) from Time 0 through 72 hours (TOpA72) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 72-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPI48</measure>
    <time_frame>0 to 48 hours</time_frame>
    <description>Time-weighted sum of pain intensity from Time 0 through 48 hours (SPI48). Lower score has a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot;. Minimum value would be &quot;0&quot; and Maximum value would be 480. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI48 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPI72</measure>
    <time_frame>0 to 72 hours</time_frame>
    <description>Time-weighted sum of pain intensity from Time 0 through 72 hours (SPI72) A lower score is a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot; Minimum value would be &quot;0&quot; and Maximum value would be 720. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI72 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">319</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>XaraColl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 placebo implants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XaraColl</intervention_name>
    <description>Surgical implantation of 3 bupivacaine collagen implants</description>
    <arm_group_label>XaraColl</arm_group_label>
    <other_name>Bupivacaine collagen implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Plain collagen implant (vehicle)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Collagen implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a planned (non-emergent) unilateral inguinal hernioplasty (open laparotomy,&#xD;
             tension-free technique) to be performed according to standard surgical technique under&#xD;
             general anesthesia. Repair of multiple hernias through a single incision is permitted&#xD;
             provided only a single mesh will be used.&#xD;
&#xD;
          -  If female, is nonpregnant and nonlactating.&#xD;
&#xD;
          -  If female, is either not of childbearing potential (defined as postmenopausal for ≥ 1&#xD;
             year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or&#xD;
             hysterectomy]) or practicing 1 of the protocol specified medically-acceptable methods&#xD;
             of birth control and agrees to continue with the regimen throughout the duration of&#xD;
             the study:&#xD;
&#xD;
          -  Has the ability and willingness to comply with the study procedures and use of the&#xD;
             eDiary.&#xD;
&#xD;
          -  Is willing to use only permitted medications throughout the study.&#xD;
&#xD;
          -  Is willing to use opioid analgesia.&#xD;
&#xD;
          -  Must be able to fluently speak and understand either English or Spanish and be able to&#xD;
             provide meaningful written informed consent for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a known hypersensitivity to amide local anesthetics, morphine, acetaminophen or&#xD;
             bovine products.&#xD;
&#xD;
          -  Is scheduled for bilateral inguinal hernioplasty or other significant concurrent&#xD;
             surgical procedures per investigator discretion.&#xD;
&#xD;
          -  Has undergone major surgery within 3 months of the scheduled hernioplasty or plans to&#xD;
             undergo another laparotomy procedure within 30 days postoperatively.&#xD;
&#xD;
          -  Has used any analgesic other than acetaminophen within 24 hours of surgery.&#xD;
             Acetaminophen may be used on the day of surgery but is subject to preoperative&#xD;
             restrictions for oral intake.&#xD;
&#xD;
          -  Has used aspirin or aspirin-containing products within 7 days of surgery. Aspirin at a&#xD;
             dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the patient has been on&#xD;
             a stable dose regimen for ≥ 30 days before Screening.&#xD;
&#xD;
          -  Has used systemic steroids, anticonvulsants, antiepileptics, antidepressants for the&#xD;
             management of chronic pain, or monoamine oxidase inhibitors on a regular basis within&#xD;
             10 days of surgery.&#xD;
&#xD;
          -  Has used any opioid analgesic for an extended daily basis (30 - 60 mg oral morphine&#xD;
             equivalent per day for 3 or more days a week) within 4 weeks before surgery. Patients&#xD;
             who, in the investigator's opinion, may be developing opioid tolerance are also&#xD;
             excluded.&#xD;
&#xD;
          -  Has any chronic painful condition (eg, fibromyalgia) or routinely uses pain medication&#xD;
             other than acetaminophen (including nonsteroidal anti-inflammatory drugs [NSAIDs])&#xD;
             that, in the opinion of the investigator, may confound the assessment of pain&#xD;
             associated with the hernioplasty.&#xD;
&#xD;
          -  Has a physical or mental condition that, in the opinion of the investigator, may&#xD;
             confound the assessment of postoperative pain after hernioplasty.&#xD;
&#xD;
          -  Shows evidence of tolerance or physical dependency on opioid analgesics or&#xD;
             sedative-hypnotic medications.&#xD;
&#xD;
          -  Has a urine drug screen that tests positive for drugs of abuse or misuse, including&#xD;
             cannabinoids.&#xD;
&#xD;
          -  Has liver function test results greater than 3x the upper limit of normal or a history&#xD;
             of cirrhosis.&#xD;
&#xD;
          -  Has any clinically significant unstable cardiac disease (eg, uncontrolled&#xD;
             hypertension, clinically significant arrhythmia at baseline, or an implantable&#xD;
             cardioverter-defibrillator [ICD])&#xD;
&#xD;
          -  Has any clinically significant unstable neurological, immunological, renal, or&#xD;
             hematological disease (eg, uncontrolled diabetes or significantly abnormal laboratory&#xD;
             findings), or any other condition that, in the opinion of the investigator, could&#xD;
             compromise the patient's welfare, ability to communicate with the study staff or&#xD;
             otherwise contraindicate study participation.&#xD;
&#xD;
          -  Has an open workman's compensation claim.&#xD;
&#xD;
          -  Has participated in a clinical trial (investigational or marketed product) within 30&#xD;
             days of surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gwendolyn Niebler, D.O.</last_name>
    <role>Study Director</role>
    <affiliation>Innocoll</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Placentia</city>
        <state>California</state>
        <zip>92870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 12, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <results_first_submitted>September 22, 2020</results_first_submitted>
  <results_first_submitted_qc>January 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2021</results_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post operative pain</keyword>
  <keyword>hernioplasty</keyword>
  <keyword>bupivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>XaraColl</title>
          <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized But Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not meet randomization criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>randomized not enrolled</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The modified intent-to-treat (mITT) population consisted of all randomized subjects who received any dose of INL-001 or placebo and who had at least 1 NRS PI score prior to hospital discharge</population>
      <group_list>
        <group group_id="B1">
          <title>XaraColl</title>
          <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="207"/>
            <count group_id="B2" value="105"/>
            <count group_id="B3" value="312"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="13.69"/>
                    <measurement group_id="B2" value="48.5" spread="13.84"/>
                    <measurement group_id="B3" value="50.0" spread="13.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SPI24</title>
        <description>The primary efficacy variable (time-weighted sum of pain intensity from Time 0 through 24 hours [SPI24]) was compared once at a 2-sided 0.05 level. Therefore, no multiplicity adjustment was necessary for the primary efficacy analysis. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot;. Minimum value would be &quot;0&quot; and Maximum value would be 240. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI24 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>modified intent-to-treat - The mITT population consisted of randomized subjects who received any dose of INL-001 or placebo and who had at least 1 NRS PI score prior to hospital discharge, as needed, to compute SPI.</population>
        <group_list>
          <group group_id="O1">
            <title>XaraColl</title>
            <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
          </group>
        </group_list>
        <measure>
          <title>SPI24</title>
          <description>The primary efficacy variable (time-weighted sum of pain intensity from Time 0 through 24 hours [SPI24]) was compared once at a 2-sided 0.05 level. Therefore, no multiplicity adjustment was necessary for the primary efficacy analysis. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot;. Minimum value would be &quot;0&quot; and Maximum value would be 240. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI24 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
          <population>modified intent-to-treat - The mITT population consisted of randomized subjects who received any dose of INL-001 or placebo and who had at least 1 NRS PI score prior to hospital discharge, as needed, to compute SPI.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3" spread="47.01"/>
                    <measurement group_id="O2" value="116.2" spread="44.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TOpA24</title>
        <description>Total use of opioid analgesia (TOpA) from Time 0 through 24 hours (TOpA24) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had to use within a 24-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
        <time_frame>Time 0 through 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XaraColl</title>
            <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
          </group>
        </group_list>
        <measure>
          <title>TOpA24</title>
          <description>Total use of opioid analgesia (TOpA) from Time 0 through 24 hours (TOpA24) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had to use within a 24-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
          <units>morphine equivalents</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.0" upper_limit="70.0"/>
                    <measurement group_id="O2" value="14" lower_limit="0.0" upper_limit="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TOpA48</title>
        <description>Total use of opioid analgesia (TOpA) from Time 0 through 48 hours (TOpA48) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 48-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
        <time_frame>Time 0 through 48 hours</time_frame>
        <population>mITT Population)</population>
        <group_list>
          <group group_id="O1">
            <title>XaraColl</title>
            <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
          </group>
        </group_list>
        <measure>
          <title>TOpA48</title>
          <description>Total use of opioid analgesia (TOpA) from Time 0 through 48 hours (TOpA48) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 48-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
          <population>mITT Population)</population>
          <units>morphine equivalent</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0.0" upper_limit="70.0"/>
                    <measurement group_id="O2" value="14" lower_limit="0.0" upper_limit="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TOpA72</title>
        <description>Total use of opioid analgesia (TOpA) from Time 0 through 72 hours (TOpA72) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 72-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
        <time_frame>Time 0 through 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XaraColl</title>
            <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
          </group>
        </group_list>
        <measure>
          <title>TOpA72</title>
          <description>Total use of opioid analgesia (TOpA) from Time 0 through 72 hours (TOpA72) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 72-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
          <units>morphine tablets</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="0.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="20" lower_limit="0.0" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SPI48</title>
        <description>Time-weighted sum of pain intensity from Time 0 through 48 hours (SPI48). Lower score has a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot;. Minimum value would be &quot;0&quot; and Maximum value would be 480. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI48 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
        <time_frame>0 to 48 hours</time_frame>
        <population>(mITT Population)</population>
        <group_list>
          <group group_id="O1">
            <title>XaraColl</title>
            <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
          </group>
        </group_list>
        <measure>
          <title>SPI48</title>
          <description>Time-weighted sum of pain intensity from Time 0 through 48 hours (SPI48). Lower score has a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot;. Minimum value would be &quot;0&quot; and Maximum value would be 480. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI48 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
          <population>(mITT Population)</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.1" lower_limit="0.0" upper_limit="435.8"/>
                    <measurement group_id="O2" value="214.9" lower_limit="0.0" upper_limit="429.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SPI72</title>
        <description>Time-weighted sum of pain intensity from Time 0 through 72 hours (SPI72) A lower score is a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot; Minimum value would be &quot;0&quot; and Maximum value would be 720. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI72 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
        <time_frame>0 to 72 hours</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>XaraColl</title>
            <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
          </group>
        </group_list>
        <measure>
          <title>SPI72</title>
          <description>Time-weighted sum of pain intensity from Time 0 through 72 hours (SPI72) A lower score is a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot; Minimum value would be &quot;0&quot; and Maximum value would be 720. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI72 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
          <population>mITT Population</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.5" lower_limit="0.0" upper_limit="651.7"/>
                    <measurement group_id="O2" value="299.7" lower_limit="62.8" upper_limit="645.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>Subject 628-018 was randomized to the INL-001 group but received placebo; the subject was included in the INL-001 group for efficacy analyses (ie, ITT and mITT populations) and was included in the placebo group for safety analyses (ie, safety population). The ITT population consisted of all randomized subjects who may or may not have received any dose of INL-001 or placebo</desc>
      <group_list>
        <group group_id="E1">
          <title>XaraColl</title>
          <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="208"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="208"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision site complication</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="208"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="208"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Incision site swelling</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="208"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="208"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="208"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="208"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="208"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="208"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charlene A. Tucker, MS Executive Director, Medical Writing and Document Management</name_or_title>
      <organization>Innocoll</organization>
      <phone>484-406-5211</phone>
      <email>ctucker@innocoll.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

